KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 102 filers reported holding KALA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,000 | -50.0% | 14,946 | -27.2% | 0.00% | – |
| Q2 2022 | $6,000 | -82.4% | 20,540 | -15.7% | 0.00% | – |
| Q1 2022 | $34,000 | +61.9% | 24,359 | +39.8% | 0.00% | – |
| Q4 2021 | $21,000 | -60.4% | 17,429 | -13.4% | 0.00% | – |
| Q3 2021 | $53,000 | -39.1% | 20,135 | +23.0% | 0.00% | – |
| Q2 2021 | $87,000 | -45.6% | 16,364 | -30.8% | 0.00% | – |
| Q4 2020 | $160,000 | +272.1% | 23,663 | +309.5% | 0.00% | – |
| Q3 2020 | $43,000 | -30.6% | 5,778 | -2.2% | 0.00% | – |
| Q2 2020 | $62,000 | +29.2% | 5,910 | -54.3% | 0.00% | – |
| Q4 2019 | $48,000 | +152.6% | 12,932 | +154.5% | 0.00% | – |
| Q3 2019 | $19,000 | +137.5% | 5,082 | +536.0% | 0.00% | – |
| Q3 2018 | $8,000 | -69.2% | 799 | -57.4% | 0.00% | – |
| Q2 2018 | $26,000 | – | 1,875 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 771,790 | $5,788,000 | 5.46% |
| RA Capital Management | 10,874,613 | $81,560,000 | 1.49% |
| Mesirow Financial Investment Management, Inc. | 36,445 | $273,000 | 1.17% |
| Samsara BioCapital, LLC | 451,162 | $3,384,000 | 0.94% |
| Parkman Healthcare Partners LLC | 310,053 | $2,325,000 | 0.62% |
| Orbimed Advisors | 5,465,030 | $40,988,000 | 0.52% |
| Eventide Asset Management | 3,450,000 | $25,875,000 | 0.51% |
| Vivo Capital, LLC | 786,883 | $5,902,000 | 0.34% |
| Ikarian Capital, LLC | 451,531 | $3,387,000 | 0.24% |
| Matisse Capital | 50,300 | $377,000 | 0.15% |